Cerebral dopamine neurotrophic factor CDNF is being tested in phase one and two clinical trials for #Parkinsons Disease treatment: https://t.co/qghls2KdnW @helsinkiuni @BIOTECH_UH @HiLIFE_helsinki #MartSaarma #HelsinkiHealth
— Life Sciences University of Helsinki (@LifeSciHelsinki) April 17, 2020 05:38